Irish-founded AI health platform Cambrean has been acquired by US health technology company Nucleus Genomics.
Cambrean’s algorithms transform data from wearables like Oura rings and Apple Watches into actionable health assessments.
Nucleus said the technology will help bridge gaps in data points to provide full-picture health insights.
The acquisition follows the successful close of a $14 million funding round by Nucleus bringing its total
funding to nearly $32 million.
“Thoughtfully integrating each data point with DNA is the way to tell the complete story about someone’s health,” said Kian Sadeghi, Founder and CEO of Nucleus.
“That’s what we plan on doing with Cambrean,” Mr Sadeghi said.
Cambrean’s research maps the relationships
between sleep, nutrition, workouts and vitals, creating algorithms that allow users to track everyday factors that impact their health.
“As we’ve gotten to know the Nucleus team, it’s become clear that we both share the same
vision for what is possible in the future of healthcare,” said David Sloane, Co-founder & CEO of Cambrean.
“Together, we’re going to combine continuous health monitoring with whole-genome sequencing for the very first time,” Mr Sloane said.
